Currently Available Treatment Tirzepatide FDA-approved and commercially available as Mounjaro/Zepbound with established dosing protocols and post-market safety data Maximum Weight Loss Potential Retatrutide Phase 3 TRIUMPH-4 data showed 28.7% weight loss at 68 weeks (24.2% at 48 weeks in Phase 2), exceeding tirzepatide's results Non-Alcoholic Fatty Liver Disease Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, showing up to 82% liver fat reduction in trials Type 2 Diabetes Management Tirzepatide Proven HbA1c reduction with FDA approval specifically for glycemic control in type 2 diabetes Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
Scientists developed the synthetic version to study its potential tissue-protective properties in a controlled laboratory setting
M., Thangthaeng, N., Miller, M
Treatment planning considers factors such as age, skin condition, previous treatments, lifestyle factors, and specific aesthetic goals
This dual activity, termed DACRA (Dual Amylin and Calcitonin Receptor Agonist), provides multiple pathways for metabolic regulation
Its primary role, as the name suggests, is to stimulate growth, cell reproduction, and regeneration